Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2007 1
2009 1
2010 1
2011 2
2012 2
2013 2
2014 2
2015 2
2016 1
2017 2
2019 2
2020 7
2021 6
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib Treatment of Steroid-Refractory Graft-versus-Host Disease in Children: A Case Series and Review of the Literature.
Yan WL, Zhao FY, Gu ME, Liu N, Guo XP, Xu XJ. Yan WL, et al. Paediatr Drugs. 2023 Sep;25(5):577-584. doi: 10.1007/s40272-023-00577-8. Epub 2023 Jun 7. Paediatr Drugs. 2023. PMID: 37284944 Review.
BACKGROUND: Ruxolitinib has been increasingly used in the treatment of steroid-refractory graft-versus-host disease (SR-GVHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) patients. ...
BACKGROUND: Ruxolitinib has been increasingly used in the treatment of steroid-refractory graft-versus-host …
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Mozo Y, Bueno D, Sisinni L, Fernández-Arroyo A, Rosich B, Martínez AP, Benítez-Carabante MI, Alonso L, Uría ML, Heredia CD, Mestre-Duran C, Pascual CFB, Torres J, Losantos I, Escudero A, Ruz-Caracuel B. Mozo Y, et al. Pediatr Hematol Oncol. 2021 May;38(4):331-345. doi: 10.1080/08880018.2020.1868637. Epub 2021 Mar 4. Pediatr Hematol Oncol. 2021. PMID: 33661711
Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults.
Moiseev IS, Morozova EV, Bykova TA, Paina OV, Smirnova AG, Dotsenko AA, Borzenkova ES, Galimov AN, Gudognikova YV, Ekushov KA, Kozhokar PV, Osipova AA, Pirogova OV, Rudakova TA, Klimova OU, Tcvetkov NY, Kulagin EA, Surkova EA, Lapin SV, Rodionov GG, Moiseev SI, Serov YA, Zubarovskaya LS, Afanasyev BV. Moiseev IS, et al. Bone Marrow Transplant. 2020 Jul;55(7):1379-1387. doi: 10.1038/s41409-020-0834-4. Epub 2020 Feb 18. Bone Marrow Transplant. 2020. PMID: 32071418
Acute and chronic steroid-refractory graft-versus-host disease (srGVHD) is a life-threatening complication of allogeneic stem cell transplantation. ...
Acute and chronic steroid-refractory graft-versus-host disease (srGVHD) is a life-threatening comp …
Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease.
Oarbeascoa G, Lozano ML, Guerra LM, Amunarriz C, Saavedra CA, Garcia-Gala JM, Viejo A, Revilla N, Acosta Fleitas C, Arroyo JL, Martinez Revuelta E, Galego A, Hernandez-Maraver D, Kwon M, Diez-Martin JL, Pascual C; Grupo Español de Aféresis – Spanish Apheresis Group. Oarbeascoa G, et al. Biol Blood Marrow Transplant. 2020 Apr;26(4):651-658. doi: 10.1016/j.bbmt.2019.12.769. Epub 2020 Jan 7. Biol Blood Marrow Transplant. 2020. PMID: 31917270 Free article.
Extracorporeal photopheresis (ECP) is an established treatment strategy in steroid-refractory graft-versus-host disease (GVHD). This study's main objective was to analyze the clinical response and impact of ECP therapy in steroid dose red …
Extracorporeal photopheresis (ECP) is an established treatment strategy in steroid-refractory graft-versus-ho …
Biomarker-guided preemption of steroid-refractory graft-versus-host disease with alpha-1-antitrypsin.
Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Gergoudis SC, et al. Blood Adv. 2020 Dec 22;4(24):6098-6105. doi: 10.1182/bloodadvances.2020003336. Blood Adv. 2020. PMID: 33351103 Free PMC article. Clinical Trial.
Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation.
Pagliuca S, Prata PH, Xhaard A, Frieri C, Giannoni L, Sutra Del Galy A, Brignier A, Sicre de Fontbrune F, Michonneau D, Dhedin N, Peffault de Latour R, Socié G, Robin M. Pagliuca S, et al. Bone Marrow Transplant. 2021 Jan;56(1):38-49. doi: 10.1038/s41409-020-0977-3. Epub 2020 Jun 25. Bone Marrow Transplant. 2021. PMID: 32587336
Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allogeneic hematopoietic stem cell transplantation (HSCT). ...
Steroid-refractory graft versus host disease (GVHD) represents a fearsome complication after allog …
35 results